[1]
|
Lenz, G. and Staudt, L.M. (2010) Aggressive Lymphomas. The New England Journal of Medicine, 362, 1417-1429.
https://doi.org/10.1056/NEJMra0807082
|
[2]
|
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. The New England Journal of Medicine, 329, 987-994.
https://doi.org/10.1056/NEJM199309303291402
|
[3]
|
Zhou, Z., Sehn, L.H., Rademaker, A.W., et al. (2014) An Enhanced International Prognostic Index (NCCN-IPI) for Patients with Diffuse Large B-Cell Lymphoma Treated in the Rituximab Era. Blood, 123, 837-842.
https://doi.org/10.1182/blood-2013-09-524108
|
[4]
|
Sehn, L.H., Berry, B., Chhanabhai, M., et al. (2007) The Re-vised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 109, 1857-1861. https://doi.org/10.1182/blood-2006-08-038257
|
[5]
|
Tay, K., Tai, D., Tao, M., et al. (2011) Relevance of the Inter-national Prognostic Index in the Rituximab Era. Journal of Clinical Oncology, 29, e14-e15. https://doi.org/10.1200/JCO.2010.31.7677
|
[6]
|
Ruppert, A.S., Dixon, J.G., Salles, G., et al. (2020) International Prognostic Indices in Diffuse Large B-Cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI. Blood, 135, 2041-2048.
https://doi.org/10.1182/blood.2019002729
|
[7]
|
Warnnissorn, N., Kanitsap, N., Niparuck, P., et al. (2022) External Validation and Comparison of IPI, R-IPI, and NCCN-IPI in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP to Predict 2-Year Progression-Free Survival. Hematology, 27, 1237-1245. https://doi.org/10.1080/16078454.2022.2147916
|
[8]
|
Shi, X., Liu, X., Li, X., et al. (2021) Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study. Frontiers in Oncology, 11, Article ID: 754964. https://doi.org/10.3389/fonc.2021.754964
|
[9]
|
Schmitz, R., Wright, G.W., Huang, D.W., et al. (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 378, 1396-1407. https://doi.org/10.1056/NEJMoa1801445
|
[10]
|
Chapuy, B., Stewart, C., Dunford, A.J., et al. (2018) Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes. Na-ture Medicine, 24, 679-690.
https://doi.org/10.1038/s41591-018-0016-8
|
[11]
|
Lacy, S.E., Barrans, S.L., Beer, P.A., et al. (2020) Targeted Se-quencing in DLBCL, Molecular Subtypes, and Outcomes: A Haematological Malignancy Research Network Report. Blood, 135, 1759-1771.
https://doi.org/10.1182/blood.2019003535
|
[12]
|
Wright, G.W., Huang, D.W., Phelan, J.D., et al. (2020) A Proba-bilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Can-cer Cell, 37, 551-568.
https://doi.org/10.1016/j.ccell.2020.03.015
|
[13]
|
Ma, J., Yan, Z., Zhang, J., et al. (2020) A Genetic Predictive Mod-el for Precision Treatment of Diffuse Large B-Cell Lymphoma with Early Progression. Biomarker Research, 8, Article No. 33.
https://doi.org/10.1186/s40364-020-00214-3
|
[14]
|
Song, J.Y., Perry, A.M., Herrera, A.F., et al. (2018) New Ge-nomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 132, 346. https://doi.org/10.1182/blood-2018-99-117636
|
[15]
|
Kline, J., Godfrey, J. and Ansell, S.M. (2020) The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. Blood, 135, 523-533. https://doi.org/10.1182/blood.2019000847
|
[16]
|
Ciavarella, S., Vegliante, M.C., Fabbri, M., et al. (2018) Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue. Annals of Oncology, 29, 2363-2370. https://doi.org/10.1093/annonc/mdy450
|
[17]
|
Ghorab, D.S., Helaly, A.M., El Mahdi, M.S., et al. (2022) Prognostic Role of Tumor Microenvironment in DLBCL and Relation to Patients’ Clinical Outcome: A Clinical and Immunohisto-chemical Study. Analytical Cellular Pathology, 2022, Article ID: 9993496. https://doi.org/10.1155/2022/9993496
|
[18]
|
Solimando, A.G., Annese, T., Tamma, R., et al. (2020) New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers, 12, 1869. https://doi.org/10.3390/cancers12071869
|
[19]
|
Kotlov, N., Bagaev, A., Revuelta, M.V., et al. (2021) Clinical and Biological Subtypes of B-Cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discovery, 11, 1468-1489.
https://doi.org/10.1158/2159-8290.CD-20-0839
|